Pulmatrix Current Ratio 2014-2022 | PULM

Pulmatrix current ratio from 2014 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Pulmatrix Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-09-30 $0.04B $0.01B 6.84
2022-06-30 $0.05B $0.01B 8.19
2022-03-31 $0.05B $0.01B 9.41
2021-12-31 $0.06B $0.00B 12.33
2021-09-30 $0.05B $0.01B 10.61
2021-06-30 $0.06B $0.01B 8.74
2021-03-31 $0.06B $0.01B 9.10
2020-12-31 $0.03B $0.01B 3.97
2020-09-30 $0.04B $0.01B 3.51
2020-06-30 $0.03B $0.02B 1.99
2020-03-31 $0.03B $0.02B 1.51
2019-12-31 $0.03B $0.02B 1.83
2019-09-30 $0.03B $0.01B 2.46
2019-06-30 $0.03B $0.01B 2.58
2019-03-31 $0.00B $0.00B 0.89
2018-12-31 $0.00B $0.00B 1.14
2018-09-30 $0.01B $0.00B 1.29
2018-06-30 $0.01B $0.00B 2.37
2018-03-31 $0.00B $0.01B 0.33
2017-12-31 $0.00B $0.01B 0.73
2017-09-30 $0.01B $0.01B 1.16
2017-06-30 $0.01B $0.01B 1.99
2017-03-31 $0.01B $0.00B 2.53
2016-12-31 $0.01B $0.01B 1.02
2016-09-30 $0.01B $0.00B 2.03
2016-06-30 $0.01B $0.00B 2.87
2016-03-31 $0.02B $0.00B 3.93
2015-12-31 $0.02B $0.00B 5.68
2015-09-30 $0.02B $0.00B 9.44
2015-06-30 $0.03B $0.00B 19.61
2015-03-31 $0.00B 0.00
2014-12-31 $0.00B $0.04B 0.02
2014-09-30 $0.01B $0.00B 22.90
2014-06-30 $0.02B $0.00B 26.63
2014-03-31 $0.02B $0.00B 16.45
2013-12-31 $0.00B 0.00
2013-09-30 $0.00B 0.00
2013-06-30 $0.00B 0.00
2013-03-31 $0.00B $0.00B 1.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.014B $0.005B
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00